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Background: Comparative proteomics has recently identiﬁed afamin, the newest member of the albumin gene
family, as a potential biomarker for ovarian cancer. The aimof this studywas the analytical and clinical evaluation
of a sandwich enzyme-linked immunosorbent assay for the determination of afamin in human plasma.
Methods:We evaluated precision, linearity, and detection limit of the assay, analyte stability and biological var-
iability, determined reference values and quantiﬁed afamin concentrations in various diseases.
Results:Within-run and total coefﬁcients of variation were b10%. The method was linear across the tested mea-
surement range. Detection limit was 7 mg/L for the assay. The analyte was stable for 24 h at room temperature,
for 48 h at 4 °C, and for at least one year at−20 °C and−80 °C. The reference change value for healthy individ-
uals was 24%. Age- and sex-independent reference values in healthy blood donors were 45–99 mg/L (median
68 mg/L). In the clinical assay evaluation afamin plasma concentrations were modestly decreased in patients
with heart failure. Patients with pneumonia or sepsis exhibited markedly decreased afamin plasma concentra-
tions. However, patients with chronic renal disease or chronic obstructive pulmonary disease showed no differ-
ence in afamin plasma concentrations as compared to healthy individuals. Correlation analyses revealed an
inverse association between afamin and inﬂammatory biomarkers.
Conclusions: The afamin assay meets quality speciﬁcations for laboratory medicine. The results of the clinical
assay evaluation revealed novel insights with respect to afamin as a potential negative acute phase protein and
should encourage further studies.© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
The glycoprotein afamin was discovered in 1994 by two indepen-
dent research groups in humans [1] and in rats [2] as the fourth
member of the albumin gene family which is located on chromosome
4q11–q13 in humans [1]. Araki et al. [3] demonstrated that afamin is
identical toα-1T-glycoprotein, a protein ﬁrst reported as a tryptophan-assay; CRP, C-reactive protein;
retic peptide; eGFR, estimated
e; CLSI, Clinical and Laboratory
nt of variation; RCV, reference
pulmonary disease.
ry Medicine, Konventhospital
tria. Tel.: +43 732 7677 3620;
plinger).
. Open access under CC BY license.poor α-1T-protein almost 50 years ago [4]. In contrast to albumin,
afamin is highly glycosylated and exerts a molecular mass of 75 kDa
[5]. Afamin has four or ﬁve potential N-glycosylation sites, and treat-
ment with N-glycanase reduces the apparent molecular mass of afamin
to 65 kDa [1]. Like other members of the albumin multigene family,
afamin consists of three structural domains indicating 17 Cys–Cys disul-
ﬁde bridges [1].
Afamin is predominantly expressed in the liver and secreted into the
bloodstream; minor expressions have been described also in human
brain [6], heart, kidney, testis and ovary (www.proteinatlas.org).
Afamin has been reported to bind vitamin E, especially α-tocopherol
and γ-tocopherol, two of the most important forms of vitamin E,
in vitro and in vivo and to possess multiple binding sites for both to-
copherol isomers [5,7].
Comparative proteomics has previously identiﬁed afamin as a
potential biomarker for ovarian cancer [8]. These ﬁndings were
conﬁrmed with immunoblotting and a quantitative immunoassay
for afamin. Patientswith ovarian cancer displayed signiﬁcantly decreased
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These results were later validated in an independent larger study of pa-
tients with ovarian cancer [9] and, very recently, extended by showing
signiﬁcant associations between afamin plasma concentrations and clin-
ical outcomes (response to therapy and survival rates) [10]. In contrast,
afamin concentrationswere not found to be decreased in benign gyneco-
logical conditions including endometriosis [9,11].
We have developed a fully automated immunoassay for the quanti-
tative measurement of afamin in human plasma. The aim of this study
was to evaluate the analytical and clinical performance of this sandwich
enzyme-linked immunosorbent assay (ELISA) for afamin.
2. Material and methods
2.1. Study protocol
Most portions of this work were derived from a single-center study
performed at the St. John of God Hospital in Linz, Austria. Remaining
portions were performed at Innsbruck Medical University, Innsbruck,
Austria. The study protocol was approved by the ethics committees of
St. John of God Hospital in Linz and Innsbruck Medical University, in
accordance with the Declaration of Helsinki. All study participants
gave informed consent. Blood was obtained by conventional veni-
puncture avoiding venous stasis. Using VACUETTE® polyethylene
terephthalate glycol blood collection tubes (Greiner Bio-One,
Kremsmünster, Austria), one anticoagulated EDTA blood sample
and one whole-blood sample were collected and plasma or serum
obtained by low-speed centrifugation for 10 min. Each study partic-
ipant underwent measurement of afamin, C-reactive protein (CRP),
procalcitonin (PCT), interleukin-6 (IL-6), creatinine, albumin, and
B-type natriuretic peptide (BNP). Further speciﬁcations of the
study protocol have been reported previously [12] and are outlined
in the respective paragraphs of this comprehensive Methods section.
2.2. Afamin measurement
Afamin was measured with photometric enzyme-linked immu-
nosorbent assay (ELISA) on a fully automated BEP® 2000 instrument
(Siemens Healthcare Diagnostics, Vienna, Austria). The afamin ELISA is
a custom-made double-antibody sandwich assay (MicroCoat GmbH,
Bernried, Germany) using an afﬁnity-puriﬁed polyclonal rabbit anti-
human-afamin antibody for coating 96-well microtiter plates and the
enzyme-conjugated monoclonal mouse anti-human afamin antibody
N13 for detection [5,7]. For a detailed description on the primary afamin
protein and antibodies used for the afamin assay, see Supplementary
data. Antibody N13 was conjugated with horse-radish peroxidase
according to standard protocols and puriﬁed by size-exclusion chroma-
tography prior to use. The biotinylated coating antibody was bound to
streptavidin-coated plates, followed by blocking unspeciﬁc binding by
incubation with 0.1% casein in phosphate-buffered-saline (PBS). After
removing blocking solution microtiter plates were sealed and kept at
4 °C until use.
All subsequent incubation steps were carried out at room tempera-
ture (18–25 °C). Antibody-coated microtiter plates were washed three
times with 300 μL of washing buffer [Tween 20 (1/2000, vol/vol) in
PBS, pH 7.3] and incubated with 100 μL blank, standards, and plasma
samples after a standard 1:1000 dilution with assay buffer (0.1% casein
in PBS, pH 7.3), washing buffer under constant agitation at 750 rpm for
60 min.
A secondary plasma standard with an afamin concentration of
80 mg/L, calibrated with puriﬁed human afamin, was used in a serial
dilution for the present study. Seven standards with the following
ﬁnal dilutions were used for each assay: S1 = 0.200 mg/L, S2 =
0.100 mg/L, S3 = 0.050 mg/L, S4 = 0.025 mg/L, S5 = 0.0125 mg/L,
S6 = 0.0063 mg/L, S7 = 0.0031 mg/L.Microtiter plates were then washed three times with 300 μL washing
buffer and incubated with 100 μL horse-radish-peroxidase-conjugated
monoclonal antibody N13 (diluted 1:2000 in assay buffer to a ﬁnal con-
centration of 1 μg/mL) under agitation at 700 rpm for 60 min. After
washing another three times with 300 μL washing buffer, 100 μL of the
chromogenic substrate solution 3,3′,5,5′-tetramethylbenzidine (TMB,
Blue Star, Adaltis, Rome, Italy) was added and the plates were ﬁnally
incubated under agitation at 700 rpm for 15–30 min. After sufﬁcient
color development, the reaction was stopped by adding 50 μL 1 N
H2SO4, followed by brief agitation and photometrical analysis at a
wavelength of 450 nm within 5 min after adding stop solution. Afamin
concentrations were calculated with a linear regression model (x axis
and y axis log transformed) after subtraction of the average blank.
In the present work, we used EDTA-plasma samples for all afamin
determinations, except for the study comparing plasma and serum
samples. Afamin was measured in each sample in duplicates on the
same microtiter plate and the mean was calculated from these two
determinations.
2.3. Further biochemical analyses
Serumconcentrations of CRP, PCT, IL-6, creatinine, albumin, and BNP
plasma concentrations were measured as reported previously by our
group [12]. Estimated glomerular ﬁltration rate was calculated using
the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation: 141 × min (creatinine [mg/dL]/κ,1)α × max (creatinine
[mg/dL]/κ,1)−1.209 x 0.993age × 1.018 [if female] × 1.159 [if black];
where κ = 0.7 if female and κ = 0.9 if male, α = −0.329 if female
and α = −0.411 if male [13].
2.4. Precision study
To evaluate the precision of the afamin assay in our laboratory,
we performed a replication study according to the Clinical and Labo-
ratory Standards Institute (CLSI; formerly NCCLS) Guideline EP5-A
[14]. Three pooled patient plasma samples were aliquoted into
twenty 1.5-mL plastic tubes for each concentration level and frozen
at −80 °C. We analyzed these samples in duplicate in one run per
day for 20 days on a single BEP® 2000 instrument within two
months of blood collection. Within-run and total analytical impreci-
sion (CVA) was calculated with the CLSI single-run precision evalua-
tion test [14].
2.5. Evaluation of linearity
We also evaluated the linearity of the afamin assay according to
the CLSI Guideline EP6-A [15] using six different analyte concentra-
tions. Fresh plasma samples were used to prepare a high- and a
low-concentration pool spanning the measurement range of the
assay. We then performed a direct dilution series with the low- and
high-concentration patient sample pools in the following volume ra-
tios (low-concentration pool + high-concentration pool): pool 1,
low only; pool 2, 0.8 low + 0.2 high; pool 3, 0.6 low + 0.4 high;
pool 4, 0.4 low + 0.6 high; pool 5, 0.2 low + 0.8 high; and pool 6,
high only. Each concentration was measured in triplicate and the de-
fault criteria were set at 5% for repeatability and 5% for nonlinearity.
2.6. Detection limit
The detection limit for the afamin assaywas determined by assaying
a diluted sample from a healthy individual in replicates of 20 and was
calculated as three standard deviations added to the resulting mean
value of the diluted sample. The diluted samplewas prepared bymixing
a fresh plasma sample in a 1:15 ratio with sample dilution buffer. This
prediluted plasma sample was then treated in the same way as all
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crotiter plate.
2.7. Stability study
We evaluated the stability of afamin concentrations (measuredwith
ELISA) after storing plasma samples from 15 patients with various dis-
eases at room temperature (RT, 18–25 °C), 4 °C,−20 °C, and −80 °C.
The stability of afamin plasma concentrations at RT and 4 °Cwas evalu-
ated after 4, 12, 24, 48 and 72 h, after seven days and after one month.
The stability of afamin at −20 °C and at −80 °C was evaluated after
24 h, after seven days, after one and six months, and after one year.
Baseline afamin plasma concentrations were determined immediately
after blood collection. At the same time, plasma samples were aliquoted
into 1.5-mLplastic tubes and stored in appropriate amounts at the spec-
iﬁed temperatures. Subsequently, these aliquots were used to measure
afamin concentrations after the speciﬁed time intervals. Mean recovery
(i.e., residual immunoreactivity) of afamin expressed in absolute values
(i.e., absolute recovery) and in percent of the initial value (i.e., relative
recovery) for the given time interval of storage was calculated. The de-
fault criterion for analyte stabilitywas set at 95%; thismeans afaminwas
considered stable at a distinct storage condition as long as the median
relative recovery was ≥95%.
2.8. Study of biological variation
Twenty-two apparently healthymembers of our laboratory staff (12
males and 10 females; age range, 22–59 years)were recruited for deter-
mination of components of biological variation (intra- and inter-
individual CV) for afamin as described previously [12] and as outlined
in the Supplementary data. Once every week for six weeks, plasma
was collected from each volunteer under standardized conditions to
minimize sources of pre-analytical variation. Intra-individual biological
CV (CVI), inter-individual biological CV (CVG), and the reference change
value (RCV) were calculated according to the methods described by
Fraser and Harris [16]. The within-run CVA value was retrieved from
our precision study.
2.9. Reference values for afamin
Reference values for the afamin assay were derived from 528
healthy blood donors at the Red Cross Organization in Linz, Austria, as
reported previously [12] and as outlined in the Supplementary data.
2.10. Afamin concentrations in serum and plasma
In order to compare afamin concentrations between serum and
plasma, one serum sample and one EDTA-plasma samplewere obtained
from each of eight apparently healthy members of our laboratory staff
(four males, four females) after an overnight fast.
2.11. Afamin concentrations in fasting and non-fasting individuals
In 25 patients (19males and 6 females) with various diseases (eight
of them with type 2 diabetes mellitus) a plasma sample was drawn at
07:00 a.m. following an overnight fast. Thereafter, all patients had a
standardized breakfast (730 kcal for patients without diabetes, and
522 kcal for thosewith diabetes). The next blood draw for afamin deter-
mination was at 11:00 a.m., after which all patients had a standardized
lunch (800 kcal for patients without diabetes, and 716 kcal for those
with diabetes). The ﬁnal blood draw was at 02:00 p.m. after lunch.
2.12. Diurnal proﬁle of afamin in healthy females
The circadian variation of afamin concentrationswas investigated by
analyzing afamin concentrations in 14 healthy non-pregnant femalesrecruited at the Department of Gynecological Endocrinology and Repro-
ductive Medicine, Innsbruck Medical University. Blood was collected
in the non-fasting state, starting at 08:00 a.m. and proceeding until
08:00 a.m. the next morning (i.e., 08:00 a.m., 12:00 p.m., 04:00 p.m.,
08:00 p.m., 12:00 a.m., 04:00 a.m., and 08:00 a.m.).
2.13. Afamin during menstrual cycle
In order to evaluate variations in afamin plasma concentrations
during the menstrual cycle, afamin was analyzed in 18 non-pregnant
females recruited at the Department of Gynecological Endocrinology
and ReproductiveMedicine, InnsbruckMedical University. Plasma sam-
ples were obtained in the early follicular phase (cycle day 3 to 5),
around the time of ovulation (cycle day 10 to 12, pre-ovulatory), and
in the mid-luteal phase (cycle day 21 to 23).
2.14. Clinical evaluation study
To examine afamin plasma concentrations in various diseases we
recruited 15 inpatients each with ‘heart failure (HF) without co-
morbidity’, ‘pneumoniawithout co-morbidity’, ‘chronic obstructive pul-
monary disease (COPD) without co-morbidity’, ‘HF with co-morbidity
of pneumonia’, ‘renal disease without co-morbidity’, or ‘sepsis’ as re-
ported previously [12] and outlined in the Supplementary data. We
used this approach to examine conditions suspected of inﬂuencing
afamin concentrations and to disentangle possible confounders. As a
control group we included the healthy individuals used for the biologi-
cal variation study with the results obtained from their ﬁrst blood
withdrawal.
2.15. Correlation of afamin with other biomarkers
To further elucidate the correlation between afamin and CRP, PCT,
IL-6, albumin, and BNP we used plasma samples from 100 patients
with a variety of diseases, as reported previously [12]. In order to eval-
uate the association between afamin and other biomarkers across a
wide range of each in diseased patients, we recruited this convenient
sample of patients with a main diagnosis of COPD (n = 25), heart fail-
ure (n = 22), renal disease (n = 16), pneumonia (n = 15), inﬂamma-
tory bowel disease (n = 12), or pulmonary embolism (n = 10)
leading to hospital admission.
2.16. Statistical analyses
Data were statistically analyzed with the SPSS 13.0 software (SPSS
Inc.) and the MedCalc 12.7.0.0 package (MedCalc Software). Relation-
ships between continuous variables were tested with the Spearman co-
efﬁcient of rank correlation (rs). Comparisons of continuous variables
between patient groups were performed with the Wilcoxon test, the
non-parametric Mann–Whitney U test, the Friedman test, or the
Kruskal–Wallis test, as appropriate. Obtained p values were not adjust-
ed for multiple comparisons and are therefore descriptive only.
3. Results
The afamin assay had awithin-run CVA of 8.7% and a total CVA of 9.9%
at a mean concentration of 26 mg/L (pool 1, low), a within-run CVA of
3.3% and a total CVA of 6.2% at a mean concentration of 73 mg/L (pool
2, medium), and a within-run CVA of 4.3% and a total CVA of 5.4% at a
mean concentration of 87 mg/L (pool 3, high).
The two high- and low-concentration plasma pools used to evaluate
the assay linearity had afamin concentrations of 77 mg/L and 18 mg/L,
respectively. The standard errors of regression (Sy,x) and t tests of
regression analyses showed that the ﬁrst-order model ﬁtted better
than did the second- and third-order models: ﬁrst-order model b1,
Sy,x = 1.4, t-test = 62.7 (p b0.001); second-order model b2, Sy,x =
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test = −0.6 (p = 0.571). In addition, all default criteria weremet. The
method was thus linear within the measured range. The detection limit
was 7 mg/L for the afamin assay.
Results of the stability study are shown in Table 1with afamin values
displayed as absolute concentrations and as percent recovery.When ap-
plying the pre-speciﬁed default criterion for analyte stability (i.e., 95% as
detailed in Material and methods), afamin was stable for 24 h at RT, for
48 h at 4 °C, and for at least one year at−20 °C and at−80 °C.
As a result of the biological variation study, the overall median for
afamin was 64 mg/L (range, 46–101 mg/L), the CVI was 7.9%, the CVG
was 14% and the RCV was 23.7%.
A histogram of afamin plasma concentrations in the healthy
blood donors indicated a non-Gaussian distribution. Of the 528
healthy blood donors, 338 (64%) were male and 190 (36%) were fe-
male. Median afamin values did not differ signiﬁcantly between
male and female individuals (68 mg/L, range 33–113 mg/L vs.
68 mg/L, range 41–106 mg/L; p = 0.739). The median age of the
healthy blood donors was 39 years (range 18–65 years). When
stratifying the blood donors by age groups no signiﬁcant differ-
ences in afamin plasma concentrations were observed across these
groups (Kruskal–Wallis test, p = 0.104). Respective median afamin
plasma concentrations according to age groups were: 18–24 years
(n = 94), 71 mg/L (range 33–106 mg/L); 25–34 years (n = 131),
66 mg/L (range 40–98 mg/L); 35–44 years (n = 128), 66 mg/L (range
43–109 mg/L); 45–54 years (n = 127), 70 mg/L (range 33–113 mg/L);
and 55–64 years (n = 48), 68 mg/L (range 38–102 mg/L). Further,
Spearman coefﬁcient of rank correlation analysis in the healthy blood
donors revealed no association between afamin plasma concentrations
and age (rs 0.043, p = 0.346). Median eGFR of the healthy blood donors
was N90 mL/min/1.73 m2 (range 59–N90 mL/min/1.73 m2). Further-
more, stratiﬁcation of the blood donors by renal function did not reveal
signiﬁcantly different afamin plasma concentrations in individuals with
an eGFR N90 mL/min/1.73 m2 (n = 402) as compared to individuals
with an eGFR b90 mL/min/1.73 m2 (n = 126); median afamin plasma
concentrations 68 mg/L (range 33–113 mg/L) vs. 68 mg/L, range
(38–109 mg/L);Mann–WhitneyU test, p = 0.827.We further calculated
reference values by using a non-parametric percentile method (95%,
double-sided). The reference interval for the afamin assay was
45–99 mg/L (median, 68 mg/L, range 33–113 mg/L; mean ± standard
deviation, 69 mg/L ± 14).
No difference in median afamin concentrations was observed
between serum and plasma samples from the same donors (73 mg/L,
range 51–88 mg/L vs. 73 mg/L, range 50–89 mg/L; Wilcoxon test,
p = 0.674).
When comparing afamin concentrations in 25 individuals in fasting
and non-fasting state, median fasting afamin plasma concentration
was 77 mg/L (range 45–104 mg/L) at 07:00 a.m., 76 mg/L (range,
47–112 mg/L; Wilcoxon test, p = 0.957 for comparison with
fasting afamin) after breakfast at 11:00 a.m., and 78 mg/L (rangeTable 1
Summary of stability results for afamin: absolute and relative analyte recoveries at distinct tim
Analyte Baseline Storage 4 h 12 h 24 h 48 h
Afamin,
mg/L
73 (52–98) RT 71 (52–100)‡ 73 (52–96)‡ 72 (48 ± 98)‡ 62 (48–90)*
4 °C 73 (49–100)‡ 76 (52–98)‡ 70 (50–95)‡ 71 (54–94)‡
−20 °C – – 72 (50–98)‡ –
−80 °C – – 73 (50–96)‡ –
Afamin,
(%)
100 RT 101 (90–108)‡ 97 (86–112)‡ 98 (75–116)‡ 89 (72–103)
4 °C 101 (92–114)‡ 98 (87–119)‡ 100 (78–118)‡ 97 (88–120
−20 °C – – 102 (85–117)‡ –
−80 °C – – 103 (89–118)‡ –
Afamin values are presented asmedian (range). In the upper part of the table, afamin plasma co
of the table, initial afamin plasma concentrationswere set at 100% to calculate percentage recov
comparisons): ***p b 0.001, **p = 0.001, *p b 0.05, ‡not signiﬁcant.36–108 mg/L; Wilcoxon test, p = 0.819 for comparison with fasting
afamin) after lunch at 02:00 p.m.
Evaluation of the diurnal proﬁle of afamin in 14 healthy females
by analyzing afamin plasma concentrations every 4 h from
08:00 a.m. to 08:00 a.m. the next morning revealed no signiﬁcant dif-
ferences among all seven time points (Friedman test, p = 0.516). In de-
tail, median afamin plasma concentrations at different time-points
were: 08:00 a.m., 71 mg/L (range 52–110 mg/L); 12:00 p.m., 71 mg/L
(range 48–107 mg/L); 04:00 p.m., 73 mg/L (range 49–111 mg/L);
08:00 p.m., 68 mg/L (range 46–113 mg/L); 12:00 a.m., 70 mg/L
(range 47–103 mg/L); 04:00 a.m., 66 mg/L (range 48–109 mg/L); and
08:00 a.m. the next morning 71 mg/L (range 51–111 mg/L).
Likewise, median afamin plasma concentrations did not differ
signiﬁcantly between the early follicular phase (65 mg/L, range,
40–110 mg/L), peri-ovulatory phase (62 mg/L, range 48–107 mg/L)
and late luteal phase (67 mg/L, range 36–117 mg/L) in healthy,
non-pregnant female probands (Friedman test, p = 0.946).
Condensed data from the clinical evaluation study are given in
Table 2. The distribution of afamin concentrations in healthy individ-
uals and diseased patients is displayed in Fig. 1. The results indicate
that there is no signiﬁcant difference in afamin plasma concentra-
tions between the control group and patients with COPD or renal dis-
ease. In contrast, mildly decreased afamin concentrations were
obtained in patients with HF, and a more pronounced decrease in
afamin concentrations was found in patients with pneumonia, HF
plus pneumonia, or sepsis.
Of the 100 patients with various diseases, 83weremale and 17were
female, median age was 69 years (range 21–85 years) and the median
afamin plasma concentrations were 50 mg/L (range 8–118 mg/L).
Spearman coefﬁcient of rank correlation analyses revealed a signiﬁcant
inverse association between afamin and CRP (rs −0.463, p b 0.001),
PCT (rs−0.234, p = 0.019), and IL-6 (rs−0.471, p b 0.001), a border-
line inverse association with BNP (rs−0.187, p = 0.063) and a signiﬁ-
cant positive association with albumin (rs +0.269, p = 0.007).4. Discussion
We aimed to conduct an analytical and clinical evaluation study of a
sandwich ELISA assay for the determination of afamin in humanplasma.
Our results demonstrate that the afamin assay meets the quality speci-
ﬁcations for laboratorymedicine. Furthermore, the results of our clinical
assay evaluation are novel regarding the analysis of afamin in various
diseases and should encourage further studies.
Within-run and total imprecision CVA of b9% and b10%, respectively,
were adequate, especially for an ELISA method. Furthermore, the assay
was linear across the testedmeasurement range. In addition, the analyte
afamin showed good stability data at different storage temperatures. As
a result of this study, afamin can be considered stable for 24 h at RT, for
48 h at 4 °C, and for at least one year at−20 °C and at−80 °C. Thus, thee points for different storage conditions.
72 h 7 days 1 month 6 months 1 year
** 64 (44–86)*** 63 (47–85)*** 66 (44–80)*** – –
65 (43–91)* 66 (47–86)*** 69 (47–82)* – –
– 72 (56–87)‡ 71 (53–88)‡ 70 (55–99)‡ 71 (50–100)‡
– 73 (57–96)‡ 75 (53–91)‡ 72 (55–100)‡ 75 (52–92)‡
*** 86 (71–108)*** 83 (69–101)*** 83 (68–105)*** – –
)‡ 92 (70–106)* 90 (76–103)*** 88 (74–107)* – –
– 97 (86–114)‡ 98 (87–109)‡ 101 (89–110)‡ 101 (89–109)‡
– 101 (90–117)‡ 99 (91–112)‡ 102 (92–112)‡ 100 (93–116)‡
ncentrations are given as absolute values for showing absolute recoveries; in the lower part
eries. Difference from respective baseline values (Wilcoxon test, not corrected for multiple
Table 2
Characteristics of study participants in the clinical evaluation study.
Disease group Gender
(m/f)
Age (years) Afamin (mg/L) CRP (mg/dL) PCT (ng/mL) IL-6 (pg/mL) eGFR (mL/min/1.73 m2) Albumin (g/dL) BNP (pg/mL)
Controls (n = 22) 12/10 38 (22–59) 63 (50–101) 0.1 (0.1–1.0) 0.1 (0.1–0.2) 2.0 (2.0–14) N90 (N90–N90) 4.5 (3.9–5.0) 17 (10–95)
HF (n = 15) 11/4 72 (57–85) 51 (36–89)** 0.6 (0.1–1.0) 0.1 (0.1–0.4) 4.6 (2.0–15) N90 (81–N90) 3.8 (2.5–6.8) 880 (519–3109)
Pneumonia (n = 15) 13/2 57 (25–84) 26 (11–65)*** 14 (2.8–29) 0.2 (0.1–2.8) 48 (7–245) N90 (81–N90) 3.0 (2.2–4.0) 66 (17–96)
COPD (n = 15) 14/1 63 (51–82) 72 (8–118)‡ 0.3 (0.1–18) 0.1 (0.1–0.4) 2.0 (2.0–16) N90 (85–N90) 4.0 (3.6–4.6) 48 (10–91)
HF + Pneum. (n = 15) 12/3 80 (55–96) 25 (11–49)*** 8.4 (5.8–30) 0.1 (0.1–2.2) 43 (10–1088) 87 (80–N90) 3.1 (1.9–4.5) 864 (539–4793)
Renal disease (n = 15) 12/3 74 (55–83) 56 (29–89)‡ 0.1 (0.1–1.0) 0.1 (0.1–0.4) 2.1 (2.0–10) 26 (9–52) 3.8 (3.2–4.6) 51 (30–96)
Sepsis (n = 15) 9/6 70 (35–83) 24 (4–55)*** 25 (7.6–35) 32 (7.0–280) 1132 (112–65500) 44 (11–N90) 2.1 (1.4–3.4) 697 (37–2575)
Data are presented as number ormedian (range). Difference in afamin concentrations for the control group vs. eachof thedisease groups (Mann–WhitneyU test, not corrected formultiple
comparisons): **p = 0.001, ***p b 0.001, ‡not signiﬁcant.
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provides unproblematic conditions for sample shipment and storage.
The reference value study in healthy blood donors revealed that
afamin plasma concentrations do not differ betweenmales and females
and are not associated with age or renal function in healthy blood do-
nors. Thus, the age- and sex-independent reference values in healthy
blood donorswere 45–99 mg/L (median 68 mg/L, range 33–113 mg/L).
The biological variation study retrieved a CVI of 7.9%, a CVG of 14%,
and a RCV of 23.7% in healthy individuals. Themagnitude of RCV is rath-
er low as compared with other analytes used in this study. For example,
RCVs for BNP or PCT have been reported to exceed 50% in healthy indi-
viduals [17,18].
No relevant difference in afamin concentrations was seen for serum
vs. plasma samples or for fasting vs. non-fasting state, indicating that
serum and plasma samples are both suitable for afamin measurement
and that afamin values can be determined independently of a patient's
fasting state.
Further evaluation of the diurnal proﬁle of afamin and the potential
inﬂuence of menstrual cycle phase on afamin in healthy females re-
vealed neither a circadian variation nor a relevant inﬂuence of menstru-
al phase on afamin plasma concentrations. Together with the data
retrieved from the biological variation study, these ﬁndings underline
the low variation of afamin over time, demonstrating good usability of
afamin for serial measurements.
In the clinical assay evaluation study median afamin concentrations
were only modestly decreased in patients with heart failure. PatientsFig. 1. Distribution of afamin plasma concentrations in healthy individuals vs. dis-
eased patients. Distribution of afamin plasma concentrations in healthy individuals
(Healthy, n = 22) compared to patients with heart failure (HF, n = 15), with pneumonia
(Pneum, n = 15), with chronic obstructive pulmonary disease (COPD, n = 15), with HF
and co-morbidity of pneumonia (HF + Pneum, n = 15), with renal disease (Renal,
n = 15), and with sepsis (Sepsis, n = 15), respectively.with pneumonia, heart failure and co-morbidity of pneumonia, as well
as sepsis exhibited markedly decreased afamin concentrations. In con-
trast, in patients with chronic renal disease or COPDwe found no differ-
ence as compared to healthy individuals. In this context it is noteworthy
that also in the correlation analysis afamin showed a rather strong in-
verse association with the inﬂammatory biomarkers CRP and IL-6.
These ﬁndings are novel, especially the strong negative association
between afamin and inﬂammatory disorders and inﬂammatory bio-
markers. Even though pathophysiology so far is unclear, afamin might
be a negative acute-phase protein.
Interestingly in this context, in our previous studies on the potential
role of afamin as a biomarker for ovarian cancer we found only moder-
ately decreased afamin plasma concentrations [8–10], e.g. median
afamin plasma concentrations were 41 mg/dL in 215 patients with
ovarian cancer [10] as compared to the rather low afamin concentra-
tions we report for inﬂammatory disorders in the present study. There-
fore, afamin plasma concentrations should be interpreted only in the
context of comorbidities and inﬂammatory biomarker status.
Very little is known about the physiological or pathophysiological
functions of afamin; large human epidemiological or animal model
studies are still lacking.
In conclusion, the afamin assay meets the quality speciﬁcations for
laboratory medicine. The analyte exerts good in vitro stability, which
is important for preanalytical issues. The biological variation of afamin
found in this studywill serve as basis for further studies looking at serial
measurements of afamin in different diseases. The results of the clinical
evaluation study revealed novel insights with respect to afamin as a po-
tential negative acute-phase protein, but raised several questionswhich
can only be answered by future research.
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